Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.26 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 12 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1634
Sealed predictions
- GATAD2A in dopamine neurons, braak-0.02 (p 0.962) → -0.19 (p 0.623)receipt 1640
Swarm cases
receipt 1640: GATAD2A in dopamine neurons, braak
- power
- full sample -0.25 (p 0.315, n 18), 95% CI -0.64 to +0.24. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.25 (p 0.323, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.228, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.16, sign flips 0; without severely affected donors -0.25 (p 0.315, n 18). fragile.
- cell type
- strongest in microglia: -0.61 (p 0.0077, n 18) vs -0.25 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GATAD2A in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GATAD2A · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.65 p 0.021 (needs p < 9.3e-4)
Receipts
loading the receipts